Skip to main content
Premium Trial:

Request an Annual Quote

Sirnaomics Inks Ocular Disease Drug Deal with Chinese Drugmaker


Sirnaomics said last week that it has signed a deal with Chinese drug company Guangdong Zhongsheng Pharmaceutical to develop siRNA-based therapeutics for diabetic retinopathy and age-related macular degeneration.

The partnership will specifically include STP601, Sirnaomics' preclinical treatment for ocular neovascularization diseases, in the Greater China and Southeast Asian markets.

Guangdong Zhongsheng has agreed to pay Sirnaomics up to $9.75 million in upfront and milestone payments under the deal, as well as royalties and market-territory sharing considerations.

Additional terms were not disclosed.